EpiBiome is a venture-backed precision microbiome engineering company working to curb the growing threat of multi-drug-resistant "superbugs" by eliminating the use of shared-class antibiotics (those shared between humans and animals) from agriculture. Instead of antibiotics, the company deploys bacteria-specific viruses that are abundant in nature and harmless to humans to treat bacterial infections. The company has garnered numerous awards and accolades, including: acceptance into the inaugural class of Illumina Accelerator; winning Johnson & Johnson’s Quick Fire Challenge; acceptance into Springboard Accelerator; winning a Bill & Melinda Gates Foundation Grand Challenges Explorations Grant; advancing from 480 companies to the final 3 in the SXSW Accelerator at the Interactive Festival; admission into StartX, Stanford’s stage-agnostic accelerator; and, most recently, winning BIO’s “Buzz of BIO” in the “Technologies of Tomorrow” category.